Predictive biomarkers of COVID-19 impact in renal transplant patients: an exploratory proteomic and cytokine analysis - Summary - MDSpire

Predictive biomarkers of COVID-19 impact in renal transplant patients: an exploratory proteomic and cytokine analysis

  • By

  • Ayodele Alaiya

  • Maha Al-Mozaini

  • Zakia Shinwari

  • Abdulaziz Alzayed

  • Ibtihaj Alsharif

  • Rabab Allam

  • Razan Bakheet

  • Layla Alharbi

  • Fahad Ojab Alotaibi

  • Jumana Idris

  • Dalia A. Obeid

  • Abeer Alshukairi

  • Marcela Márquez-Méndez

  • Ricardo M. Cerda-Flores

  • Hamad A. Almojalli

  • June 12, 2026

  • 0 min

Share

Objective:

To identify immune and proteomic biomarkers associated with COVID-19 in renal transplant patients (RTPs) to improve disease characterization and support future diagnostic and therapeutic strategies.

Approach:
    Key Findings:
    • Add context regarding cytokine expression variation related to disease phases.
    Interpretation:

    Remove unsupported conclusions.

    Limitations:
    • Small sample size limits generalizability.
    • Only surviving patients were included in the study.
    Conclusion:

    Validation in larger and more diverse cohorts is warranted.

Original Source(s)

Predictive biomarkers of COVID-19 impact in renal transplant patients: an exploratory proteomic and cytokine analysis

  • by Ayodele Alaiya, Maha Al-Mozaini, Zakia Shinwari, Abdulaziz Alzayed, Ibtihaj Alsharif, Rabab Allam, Razan Bakheet, Layla Alharbi, Fahad Ojab Alotaibi, Jumana Idris, Dalia A. Obeid, Abeer Alshukairi, Marcela Márquez-Méndez, Ricardo M. Cerda-Flores, Hamad A. Almojalli

  • June 12, 2026

Related Content

FDA Approves Ensitrelvir to Prevent COVID-19 After Exposure

Phase 3 data showed a 67% reduction in symptomatic infection among exposed household contacts who tested negative at baseline.

Retraction: Assessing the Causal Association Between COVID-19 and Graves Disease: Mendelian Randomization Study

Explainable machine learning-based mortality risk stratification for older adults with COVID-19: pinpointing core immunological biomarkers and revealing dose-threshold effects